Natixis Advisors LLC Buys 1,379 Shares of argenx SE (NASDAQ:ARGX)

Natixis Advisors LLC raised its stake in argenx SE (NASDAQ:ARGX - Free Report) by 13.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 12,014 shares of the company's stock after acquiring an additional 1,379 shares during the quarter. Natixis Advisors LLC's holdings in argenx were worth $6,513,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in ARGX. Profund Advisors LLC boosted its stake in shares of argenx by 3.0% in the second quarter. Profund Advisors LLC now owns 973 shares of the company's stock valued at $418,000 after buying an additional 28 shares during the period. Wealth Alliance increased its position in shares of argenx by 4.8% in the second quarter. Wealth Alliance now owns 628 shares of the company's stock worth $270,000 after purchasing an additional 29 shares during the period. GAMMA Investing LLC raised its stake in argenx by 51.3% in the second quarter. GAMMA Investing LLC now owns 118 shares of the company's stock valued at $51,000 after purchasing an additional 40 shares in the last quarter. Toronto Dominion Bank boosted its position in shares of argenx by 16.5% during the 1st quarter. Toronto Dominion Bank now owns 303 shares of the company's stock worth $119,000 after acquiring an additional 43 shares in the last quarter. Finally, Sequoia Financial Advisors LLC raised its holdings in shares of argenx by 3.1% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 1,713 shares of the company's stock worth $737,000 after buying an additional 52 shares in the last quarter. Institutional investors own 60.32% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on ARGX shares. JMP Securities raised their target price on shares of argenx from $497.00 to $606.00 and gave the company a "market outperform" rating in a research report on Friday, November 1st. Wolfe Research raised shares of argenx from a "peer perform" rating to an "outperform" rating and set a $697.00 target price on the stock in a report on Tuesday, November 12th. Truist Financial raised their price target on shares of argenx from $540.00 to $660.00 and gave the company a "buy" rating in a research note on Thursday, October 31st. Guggenheim raised their target price on argenx from $585.00 to $665.00 and gave the stock a "buy" rating in a research report on Friday, November 1st. Finally, Piper Sandler raised their price objective on argenx from $553.00 to $620.00 and gave the stock an "overweight" rating in a research report on Friday, November 1st. Three equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $630.42.

argenx Trading Up 1.5 %

Shares of NASDAQ:ARGX traded up $9.18 during mid-day trading on Friday, reaching $605.92. The company had a trading volume of 363,517 shares, compared to its average volume of 325,269. argenx SE has a one year low of $327.73 and a one year high of $611.22. The company's 50-day moving average price is $557.73 and its 200-day moving average price is $488.21. The firm has a market cap of $36.23 billion, a price-to-earnings ratio of -688.55 and a beta of 0.61.

argenx (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings results on Thursday, October 31st. The company reported $1.39 EPS for the quarter, beating analysts' consensus estimates of $0.10 by $1.29. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The firm had revenue of $588.88 million for the quarter, compared to analysts' expectations of $543.29 million. During the same quarter in the prior year, the firm earned ($1.25) EPS. On average, research analysts anticipate that argenx SE will post 2.2 EPS for the current fiscal year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.